Xenon Pharmaceuticals Inc. has announced positive topline results from the Phase 3 X-TOLE2 study of azetukalner, a novel KV7 potassium channel opener, in treating focal onset seizures. This milestone underscores the company’s commitment to advancing life-changing therapeutics for patients with epilepsy and depression.